LASER-tissue interactions

As new laser devices continue to emerge, it becomes increasingly important for the clinical dermatologist to understand the basic principles behind their operation. A fundamental understanding of how lasers interact with tissue will enable the physician to choose the most appropriate laser for a given clinical situation. Although the physical laws guiding laser design are vastly complex, the fundamental principles of laser-tissue interaction can be summarized as they are applicable to the clinician.     

伊拉克中医药发展现状与分析

伊拉克是位于亚洲西南部、阿拉伯半岛东北部的多民族、多宗教联邦制国家。医疗保险以初级卫生保健模式为主,私营医疗保健为辅。伊拉克的传统医学以伊斯兰医学为主。2000年,在我国政府支持下伊拉克建立了中医中心,但因安全问题,中心的管理与经营存在人员不足、水平有限、后续支持难以持久等问题。目前,中医药尚未纳入伊拉克医疗保险体系,从一定程度上影响了民众的就医选择,阻碍了中医药的发展。建议通过加强现有中医中心建设,提高中医药教育的可及性,加强两国传统医学的合作与交流,以促进中医药在伊拉克的传播与发展。     

紫杉醇注射液对一次性使用精密输液器中邻苯二甲酸二(2- 乙基)己酯的溶出作用

以紫杉醇注射液为浸提液,模拟临床最恶劣使用条件,建立高效液相色谱（HPLC）测定一次性使用输液器中邻苯二甲酸二（2-乙基）己酯（DEHP）溶出量的检测方法,评价紫杉醇注射液临床使用的安全性。     

科曼远程监护解决方案

随着时代科技不断更新发展,目前的监护需求已不再局限于医院内部。传统的患者与医生之间面对面的诊断模式已经不能满足人们对健康保健日益增长的巨大需求。传统诊断模式在时间以及资源的利用效率上有待进一步提高,这些都对医疗保健行业提出了巨大的挑战。因此,利用穿戴式生理检测技术应运而生,其不但能够实现长期、持续的检测,而且能对使用者的健康状况以及生理信息进行实时的显示,有助于医生对用户实施定期监测以及远程会诊。     

Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension

ObjectiveTo evaluate the safety of phosphatidylserine (PS) enriched with omega3 fatty acids, mainly eicosapentaenoic (PS-Omega3) in children with attention-deficit hyperactivity disorder (ADHD).MethodsTwo hundred children diagnosed with ADHD were randomised to receive either PS-Omega3 (300 mg PS-Omega3/day) or placebo for 15 weeks. One hundred and fifty children continued into an open-label extension for an additional 15 weeks in which they all consumed PS-Omega3 (150 mg PS-Omega3/day). Standard blood biochemical and haematological safety parameters, blood pressure, heart rate, weight and height were evaluated. Adverse events and the Side Effect Rating Scale were also assessed.ResultsOne hundred and sixty-two participants completed the double-blind phase. No significant differences were noted between the two study groups in any of the safety parameters evaluated. One hundred and forty participants completed the open-label phase. At the end of this phase, no significant changes from baseline were observed in any of the studied parameters among participants who consumed PS-Omega3 for 30 weeks.ConclusionsStudy results demonstrate that consumption of PS-Omega3 by children with ADHD, as indicated in a 30-week evaluation period, is safe and well tolerated, without any negative effect on body weight or growth.